Table 3.

Effect of 40 months of intervention of Omega-3 fatty acids on decline in creatinine–cystatin C-based kidney function in 2344 patients of the Alpha Omega Trial with or without CKD at baseline according to treatment group

Treatment GroupsCreatinine–Cystatin C-based eGFR (ml/min per 1.73 m2)a
Pretreatment (Mean±SD)Post-Treatment (Mean±SD)Decline (Mean±SD)Treatment Effect Mean (95% CI)b
≥60 ml/min per 1.73 m2
 Placebo (n=500)85.0±13.177.4±16.5−7.6±12.5
 ALA (n=503)85.1±14.178.0±17.0−7.1±12.80.6 (−1.0 to 2.1)
 EPA-DHA (n=467)84.9±12.978.5±15.8−6.4±12.61.3 (−0.3 to 2.9)
 EPA-DHA plus ALA (n=468)84.2±12.777.2±15.2−7.1±12.70.6 (−1.0 to 2.2)
<60 ml/min per 1.73 m2
 Placebo (n=93)48.2±10.145.4±15.4−2.8±12.3
 ALA (n=98)47.7±9.445.7±14.9−2.0±11.70.9 (−2.6 to 4.3)
 EPA-DHA (n=109)49.4±8.651.5±16.92.1±14.84.9 (1.1 to 8.7)
 EPA-DHA plus ALA (n=106)48.6±10.247.2±17.9−1.4±13.11.4 (−2.2 to 5.0)
  • a On the basis of the Chronic Kidney Disease Epidemiology Collaboration equation of 2012 (15). CKD was defined as eGFR<60 ml/min per 1.73 m2.

  • b Decline in intervention group minus decline in placebo group with 95% CI. The P value for interaction with regard to change of eGFR between CKD at baseline (yes or no) and ALA versus placebo was 0.67; for EPA-DHA versus placebo, P for interaction was 0.07, and for EPA-DHA plus ALA versus placebo, P value for interaction was 0.89.